Acute disseminated encephalomyelitis after severe acute respiratory syndrome coronavirus 2 vaccination: a case report.

Dear Editor:

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection outbreak is a global pandemic defined by the World Health Organization, and vaccines are well into development. Vaccine safety is not described, and severe neurological complications may occur [1]. Acute disseminated encephalomyelitis (ADEM) is an immune-mediated demyelinating disease with diverse clinical manifestations, extensive central nervous system white matter involvement, and multiple risk factors, including vaccines [2, 3]. ADEM generally has a favorable outcome.

A 24-year-old woman was admitted after a 1-day memory decline with headache, low-grade fever, muscle stiffness, extremity weakness, and reduced appetite. She reported no upper respiratory infection or diarrhea. Two weeks prior, she received a SARS-CoV-2 vaccine, including 4 μg inactivated SARS-CoV-2 (Vero Cells, Beijing Institute of Biological Products Co., Ltd., Beijing, China). She has no significant medical history. Neurological examination showed somnolence and memory decline, although other neurological tests were within normal limits. Her Mini-Mental State Examination (MMSE) score was 11 out of 30.

Upon hospitalization, the cerebrospinal fluid (CSF) white blood cell (WBC) count was 51 × 106/L (reference range, 0–10 × 106/L). Two days later, a repeat CSF examination showed a WBC count of 25 × 106/L. CSF was negative for antibodies to major pathogens and cultures of bacteria and fungi; high-throughput genome sequencing also revealed no pathogens. SARS-CoV-2 antibodies were negative in the CSF on day 1 and in her blood on day 2 after admission. SARS-CoV-2 immunoglobulin G was present in the blood on day 5 after admission. Oligoclonal bands in blood and CSF were negative, and CSF antibodies, including anti-aquaporin-4, anti-myelin basic protein, anti-myelin oligodendrocyte glycoprotein, anti-glial fibrillary acidic protein, autoimmune encephalitis, and paraneoplastic syndrome, were negative. Six nasal swab tests for SARS-CoV-2 nucleic acid amplification performed at different times during hospitalization were negative. HIV, autoimmune vasculitis, anticardiolipin, and anti-nuclear antibody tests of blood were all negative.

Initial brain magnetic resonance imaging (MRI) showed abnormal signals in the bilateral temporal cortex (Fig. 1a–h). Repeat brain MRI on day 10 showed an increased number of lesions, which were more striking in appearance (Fig. 1i–l); the lesions were improved by day 15 (Fig. 1m–p). The patient was administered intravenous (IV) ceftriaxone 2 g/days for 12 days and acyclovir 1.5 g/days for 16 days. Her headache, low-grade fever, and muscle aches were relieved while undergoing during treatment, although her poor memory persisted. She had a generalized tonic–clonic seizure 1 week after admission. An electroencephalogram showed epileptiform waves. She was immediately administered IV diazepam 10 mg and oral levetiracetam 1 g/days, with no seizure recurrence. She was administered IV immunoglobulin 20 g/days for 5 days starting on day 11, and her MMSE scores improved to 29/30 on day 15. On a visit 1 month after discharge, she felt no discomfort, and a repeat MRI showed complete resolution of brain lesions.

Fig. 1

MRI studies during hospitalization. Day 2 after hospitalization: T2-weighted imaging (WI; a arrow), diffusion-WI (b arrow), contrast-enhanced MRI (c), and MR angiography (d) show no obvious abnormality. Fluid-attenuated inversion recovery (FLAIR, e–h, arrows) imaging shows hyperintense signals, while T1-WI (e) shows low signals in the bilateral temporal cortices. Day 10 after hospitalization: repeat FLAIR imaging (i–l, arrows) reveals an increase in the number of lesions and their more striking appearance. Day 15 after hospitalization: repeat FLAIR imaging (m–p, arrows) shows an improvement in the lesions

Our patient met the diagnostic criteria set by the International Pediatric MS Study Group [4], and alternative diagnoses, such as infectious or autoimmune encephalitis, were excluded in our patient. ADEM following vaccination is a well-known entity and is, hence, not surprising following SARS-CoV-2 vaccination. In this case, a protective antibody was produced after vaccination. MRI typically shows reversible, large (> 1–2 cm), bilateral, white matter lesions, and deep gray matter lesions of the brain. CSF analysis may reveal a mild pleocytosis and elevated protein levels, but it is generally negative for intrathecal oligoclonal immunoglobulin G synthesis [2]. Systemic corticosteroids are first-line therapy [5], and patients have an excellent response to gamma-globulin [6].

A brief literature review did not identify a case similar to ours. ADEM has not been reported following SARS-CoV-2 vaccination, although it is a possibility. Patients with CNS findings should be enquired about recent vaccinations for a quick and accurate diagnosis to initiate treatment and prevent serious sequelae.